A randomized trial of directly administered antiretroviral therapy and adherence case management intervention

被引:76
|
作者
Wohl, AR
Garland, WH
Valencia, R
Squires, K
Witt, MD
Kovacs, A
Larsen, R
Hader, S
Anthony, MN
Weidle, PJ
机构
[1] Los Angeles Cty Dept Hlth Serv, HIV Epidemiol Program, Los Angeles, CA 90005 USA
[2] Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90089 USA
[3] Univ So Calif, Los Angeles Cty Med Ctr, Los Angeles, CA 90033 USA
[4] Harbor UCLA Med Ctr, David Geffen Sch Med, Los Angeles Biomed Res Unit, Torrance, CA 90509 USA
[5] Ctr Dis Control & Prevent, Atlanta, GA USA
关键词
D O I
10.1086/503906
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. A randomized, controlled trial was conducted to evaluate the impact of a directly administered antiretroviral therapy program (DAART) and intensive adherence case management (IACM) intervention on virologic and immunologic response to highly active antiretroviral therapy (HAART) among patients at 3 public human immunodeficiency virus clinics in Los Angeles County, California. Methods. Participants included 250 treatment-naive and treatment-experienced persons for whom no more than 1 prior HAART regimen had failed. Five days per week for 6 months, a community worker delivered 1 HAART dose to DAART participants and observed the participant take it. IACM participants met weekly with a case manager to overcome barriers to HAART adherence. A control group (the standard of care [SOC] group) received the usual care. Results. The majority of patients were Latino (64%) or African American (24%); 57% were monolingual Spanish speakers. Seventy-five percent of the patients were male, and 64% reported an annual income of <$10,000. In an intent-to-treat analysis, no statistical differences were observed in the percentage of patients with an undetectable viral load (i.e., < 400 copies/mL) at 6 months between the DAART group (54%), IACM group (60%), and SOC group (54%; P > .05). An on-treatment analysis determined that there were no statistical differences in the percentage of patients with an undetectable viral load at 6 months between the DAART group (71%), IACM group (80%), and SOC group (74%; P > .05). Additionally, there were no statistical differences in 6-month changes in the CD4(+) cell count or in self-reported adherence to therapy. Conclusions. Among patients with limited prior HAART experience and adherence barriers that had not been assessed before randomization, no differences were found in virologic or immunologic response for DAART or IACM, compared with SOC, at 6 months. DAART and IACM did not improve short-term outcomes when SOC included other means of adherence support that were not controlled for by the study design.
引用
收藏
页码:1619 / 1627
页数:9
相关论文
共 50 条
  • [1] Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy
    Maru, Duncan Smith-Rohrberg
    Bruce, R. Douglas
    Walton, Mary
    Mezger, Jo Anne
    Springer, Sandra A.
    Shield, David
    Altice, Frederick L.
    [J]. AIDS AND BEHAVIOR, 2008, 12 (02) : 284 - 293
  • [2] Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy
    Duncan Smith-Rohrberg Maru
    R. Douglas Bruce
    Mary Walton
    Jo Anne Mezger
    Sandra A. Springer
    David Shield
    Frederick L. Altice
    [J]. AIDS and Behavior, 2008, 12 : 284 - 293
  • [3] Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy:: prospective randomized trial
    Weber, R
    Christen, L
    Christen, S
    Tschopp, S
    Znoj, H
    Schneider, C
    Schmitt, J
    Opravil, M
    Günthard, HF
    Ledergerber, B
    [J]. ANTIVIRAL THERAPY, 2004, 9 (01) : 85 - 95
  • [4] Directly administered antiretroviral therapy: Pilot study of a structural intervention in methadone maintenance
    Sorensen, James L.
    Haug, Nancy A.
    Larios, Sandra
    Gruber, Valerie A.
    Tulsky, Jacqueline
    Powelson, Elisabeth
    Logan, Deborah P.
    Shapiro, Bradley
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2012, 43 (04) : 418 - 423
  • [5] Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs
    Bernadette Anna Mullen
    Katie Cook
    Richard D Moore
    Cynthia Rand
    Noya Galai
    Mary E McCaul
    Sheldon Glass
    Krisann K Oursler
    Gregory M Lucas
    [J]. BMC Infectious Diseases, 11
  • [6] Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs
    Mullen, Bernadette Anna
    Cook, Katie
    Moore, Richard D.
    Rand, Cynthia
    Galai, Noya
    McCaul, Mary E.
    Glass, Sheldon
    Oursler, Krisann K.
    Lucas, Gregory M.
    [J]. BMC INFECTIOUS DISEASES, 2011, 11
  • [7] Managed Problem Solving for Antiretroviral Therapy Adherence A Randomized Trial
    Gross, Robert
    Bellamy, Scarlett L.
    Chapman, Jennifer
    Han, Xiaoyan
    O'Duor, Jacqueline
    Palmer, Steven C.
    Houts, Peter S.
    Coyne, James C.
    Strom, Brian L.
    [J]. JAMA INTERNAL MEDICINE, 2013, 173 (04) : 300 - 306
  • [8] Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578)
    Wagner, Glenn J.
    Kanouse, David E.
    Golinelli, Daniela
    Miller, Loren G.
    Daar, Eric S.
    Witt, Mallory D.
    Diamond, Catherine
    Tilles, Jeremiah G.
    Kemper, Carol A.
    Larsen, Robert
    Goicoechea, Miguel
    Haubrich, Richard H.
    [J]. AIDS, 2006, 20 (09) : 1295 - 1302
  • [9] Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: A prospective, randomized, controlled trial
    Altice, Frederick L.
    Maru, Duncan Smith-Rohrberg
    Bruce, R. Douglas
    Springer, Sandra A.
    Friedland, Gerald H.
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 45 (06) : 770 - 778
  • [10] Directly administered antiretroviral therapy for HIV-Infected drug users does not have an impact on antiretroviral resistance - Results from a Randomized controlled trial
    Maru, Duncan Smith-Rohrberg
    Kozal, Michael J.
    Bruce, R. Douglas
    Springer, Sandra A.
    Altice, Frederick L.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (05) : 555 - 563